Citius shares surge 13.46% premarket as LYMPHIR expansion into Turkey and Gulf markets advances.

Citius Oncology surged 13.46% in premarket trading following two key developments: the FDA approval of LYMPHIR for cutaneous T-cell lymphoma and an expanded international distribution partnership. The company secured exclusive distribution rights with Er-Kim to expand LYMPHIR’s availability in Turkey and Gulf Cooperation Council (GCC) nations, extending its global footprint to 19 international markets. While the FDA approval was highlighted as a regulatory milestone, the partnership addresses commercialization challenges by leveraging Er-Kim’s local expertise in sales, marketing, and reimbursement, directly countering concerns about LYMPHIR’s market viability. The combined progress in regulatory and market expansion likely drove the sharp premarket rally.